Tag: Fresenius Kabi

Polpharma and Fresenius Kabi License Vedolizumab Biosimilar

August 5, 2025

Polpharma Biologics S.A. has announced a global licensing agreement with Fresenius Kabi for the commercialization of PB016, a proposed biosimilar to vedolizumab. The agreement excludes

Jill Thompson and Harold Kisner Join CLEU Diagnostics Advisory Board

FDA Grants Interchangeable Designation to Fresenius Kabi’s biosimilar Otulfi

May 19, 2025

Fresenius Kabi, an operating company of Fresenius, and Formycon AG, announced that the U.S. Food and Drug Administration (FDA) designated Otulfi (ustekinumab-aauz) as an interchangeable

CMS Grants Fresenius Kabi Permanent, Product-Specific Q-Code for Otulfi

April 29, 2025

Measures will streamline claims, reimbursement effective April 2025 Fresenius Kabi, an operating company of Fresenius, announced that the Centers for Medicare and Medicaid Services issued

Categories

Tag: Fresenius Kabi

Polpharma and Fresenius Kabi License Vedolizumab Biosimilar

FDA Grants Interchangeable Designation to Fresenius Kabi’s biosimilar Otulfi

CMS Grants Fresenius Kabi Permanent, Product-Specific Q-Code for Otulfi

Share With

Recent Posts

AngioInsight Adds Shlomi Nachman to Board, Raises Series A

Gilead Shares New Data on Livdelzi and Bulevirtide

Vertex Shares New Cystic Fibrosis Data at NACFC

BluHaven Redefines Infusion Centers with First Location In Raleigh

US Acute Care Solutions Launches JACI: An Online, Peer-Reviewed Journal

Quick Links

Insights

Get in touch

Follow Us

Our Other Brands